Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes

doi:10.4251/wjgo.v18.i6.117912

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(22)

(0)

(374)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jun 15, 2026; 18(6): 117912
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117912

Table 3 Comparison of tumor marker indicators between the two groups, mean ± SD

Indicators	Time	Control group (n = 80)	Experimental group (n = 80)	t/χ²	P value
Carcinoembryonic antigen	Before treatment	15.95 ± 3.53	16.83 ± 3.49	-1.587	0.115
Carcinoembryonic antigen	After treatment	4.52 ± 1.15	3.59 ± 1.24	4.942	< 0.001
Carbohydrate antigen 19-9	Before treatment	86.48 ± 3.99	87.35 ± 3.85	-1.405	0.162
Carbohydrate antigen 19-9	After treatment	34.57 ± 7.23	31.51 ± 6.43	2.833	0.005

It compares the levels of tumor markers (carcinoembryonic antigen and carbohydrate antigen 19-9) before and after treatment between the control and experimental groups using independent samples t-tests. The results show that while no significant differences existed at baseline (P > 0.05), the experimental group exhibited significantly greater reductions in both carcinoembryonic antigen and carbohydrate antigen 19-9 levels after treatment compared to the control group (P < 0.05).

Full Size Table

Citation: Liu B, Su N, Lin QS, Huang YQ, Chen SF. Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes. World J Gastrointest Oncol 2026; 18(6): 117912
URL: https://www.wjgnet.com/1948-5204/full/v18/i6/117912.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i6.117912

Liu B, Su N, Lin QS, Huang YQ, Chen SF. Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes. World J Gastrointest Oncol 2026; 18(6): 117912 [DOI: 10.4251/wjgo.v18.i6.117912]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.